Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. | Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer.

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1, a protein that helps to keep the body's immune responses under control.

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck's pre-clinical and clinical bioanalytical workflows onto one flexible,